Autocrine PD-1-blocking nanobodies enhance the antitumor efficacy of TCR-like CAR-T cells by attenuating t cell exhaustion
Chimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable success in hematologic malignancies, but its efficacy against solid tumors is severely limited by two core barriers: the scarcity of uniformly expressed tumor-associated antigens (TAAs) and the immunosuppressive tumor microenvironment (TME), in wh...